The study of acute toxicity of 1,3-oxazole-4-il-phosphonic acid derivative in intraperitoneal administration

Authors

  • I. V. Nizhenkovska O.O.Bohomolets National Medical University, Ukraine
  • V. K. Sedko O.O.Bohomolets National Medical University, Ukraine
  • O. V. Golovchenko Institute of Bioorganic Chemistry and Petrochemistry NAS of Ukraine, Ukraine
  • O. I. Golovchenko O.O.Bohomolets National Medical University, Ukraine

DOI:

https://doi.org/10.24959/nphj.18.2186

Keywords:

derivative of 1, 3-oxazole-4-yl-phosphonic acid, OVP-1, acute toxicity, intraperitoneal administration, mice, mid-lethal dose

Abstract

The derivative of 1,3-oxazole-4-yl-phosphonic acid (OVP-1) has the vasodilatory activity and is studied as a potential antihypertensive agent. The toxicological assessment plays an important role in the preclinical study of new drugs.

Aim. To study the acute toxicity of OVP-1 in intraperitoneal administration and determine its average lethal dose.

Materials and methods. The intraperitoneal route of administration was chosen as it provides the systemic action of drugs. The experiment was conducted on female and male of white non-linear mice. Five experimental groups of animals corresponded to such dose levels of OVP-1 as 1000 mg/kg, 3000 mg/kg, 3500 mg/kg, 4000 mg/kg, and 4500 mg/kg. The solution of 1,3-oxazole-4-yl-phosphonic acid derivative and the blank solution (the mixture of Tween-80 and water for injection in the ratio of 1 : 10) was injected once in the abdominal cavity of mice. They were monitored for their mortality, behavior, and clinical characteristics over the following 14 days. LD50 of OVP-1 was determined by the number of dead animals before autopsy.

Results and discussion. As a result of the experiment the peculiarities of the toxic effect of 1,3-oxazole-4-yl-phosphonic acid derivative on the organism of the experimental mice have been studied. Based on clinical observations there were no changes in the behavior and appearance of mice for 14 days. However, taking into account the rare cases of tachypnea, piloerection and catalepsy, it can be assumed that OVP-1 in toxic doses can affect the central nervous system, the autonomic system, and there is a probability of occurrence of cardio-pulmonary insufficiency.

Conclusions. It has been determined that LD50 of OVP-1 derivative in intraperitoneal administration to mice of both sexes is 3350.67 ± 54.62 mg/kg and belongs to the toxicity class VI – relatively harmless compounds, which makes this compound promising for further preclinical pharmacological studies.

Author Biographies

I. V. Nizhenkovska, O.O.Bohomolets National Medical University

Doctor of Medicine (Dr. habil.), professor, head of the Department of Pharmaceutical

V. K. Sedko, O.O.Bohomolets National Medical University

teaching assistant of the Department of Pharmaceutical, Biological and Toxicological Chemistry

O. V. Golovchenko, Institute of Bioorganic Chemistry and Petrochemistry NAS of Ukraine

Candidate of Chemistry (Ph.D.), senior researcher

O. I. Golovchenko, O.O.Bohomolets National Medical University

teaching assistant Department of Pharmaceutical, Biological and Toxicological Chemistry

References

Salomone, S. (2010). Analytical and Experimental Pharmacology, Challenges Ahead. Frontiers in Pharmacology, 1. doi: 10.3389/fphar.2010.00119

Stefanov, O. V. (2001). Doklinichni doslidzhennia likarskykh zasobiv. Kyiv: Avitsenna, 59–90.

Nizhenkovska, I.V. et al. (2015). Farmakolohiia ta likarska toksykolohiia, 6, 76–83.

Sedko, К. V. et al. (2016). Ukrainskyi naukovo–medychnyi molodizhnyi zhurnal, 1, 108–112.

Yakovenko, I.N., Lukashuk, O. I., Kondratiuk, K. M. et al. (2013). Zhurnal orhanichnoi i farmatsevtychnoi khimii – Journal of Organic and Pharmaceutical Chemistry, 11 (3), 44–50.

Kozhemiakin, Yu. M., Khromov, O. S., Filonenko, M. A., Saifetdinova, H .A. (2002). Naukovo–metodychni rekomendatsii z utrymannia laboratornykh tvaryn ta roboty z nymy. Kyiv: Avitsenna, 156.

European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes. Available at: https://rm.coe.int/168007a67b

Downloads

Published

2018-03-15

Issue

No. 1(93) (2018)

Section

Experimental and Clinical Pharmacology

License

Copyright (c) 2018 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).